Logo
x

Search

Subscribe Now

Non-Exclusive

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II S...

  • October 8, 2021
Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

  • April 1, 2020
Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in I...

  • July 11, 2019
Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors

Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumo...

  • July 10, 2019
Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

  • April 11, 2019
Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

  • April 5, 2019
Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

    Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in I...

    • July 11, 2019
    Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors

      Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumo...

      • July 10, 2019
      Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

        Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

        • April 11, 2019
        Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

          Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

          • April 5, 2019
          Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

            Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

            • March 29, 2019
            Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

              Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

              • February 21, 2019
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.